SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Care-plan review) — Audre Lorde — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAudre Lorde
Date of birth1934-02-18
IdentifiersMRN HR-ML016-SYN-TD; SSN (made up) 000-16-2937
Document date1979-09-28
AuthorNaomi Fairweather, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Survivorship visit one year after diagnosis, after the yearly mammogram. [S]

History of Present Illness

Ms. Lorde returns one year after her diagnosis. Her diagnostic mammogram of the left breast a week ago showed no suspicious findings (BI-RADS 1). She has taken tamoxifen daily for eleven months. Her hot flashes remain mild, one or two a day. Her periods are regular with no bleeding between them. She has no leg swelling, breathlessness, bone pain, cough, headaches, abdominal pain, or new lumps, and no arm swelling. She walks about 30 minutes most days. Her genetic counseling appointment is next week. [S]

ElementDetail
Interval changeLeft mammogram BI-RADS 1 a week ago
TamoxifenEleven months, taken daily
Recurrence symptomsNone
GynecologicRegular periods; no intermenstrual bleeding
Genetic counselingNext week

Review of Systems

SystemResultFinding
ConstitutionalNegativeWeight stable; no night sweats
EndocrinePositiveOne or two mild hot flashes a day
GenitourinaryNegativeNo abnormal vaginal bleeding
CardiovascularNegativeNo leg swelling or chest pain
RespiratoryNegativeNo cough or breathlessness
MusculoskeletalNegativeNo bone pain
PsychiatricNegativeMood good; PHQ-2 score 0

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five yearsOne tablet once dailyOral route1978-10-27activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1979-09-28Body height168cmS
1979-09-28Body weight71.8kgS
1979-09-28Body mass index (BMI) [Ratio]25.4kg/m2S
1979-09-28Systolic blood pressure120mm[Hg]S
1979-09-28Diastolic blood pressure76mm[Hg]S
1979-09-28Heart rate72/minS
1979-09-28Respiratory rate14/minS
1979-09-28Body temperature36.6CelS
1979-09-28Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1979-09-28Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 1979-09-28; see the Vital Signs section. [S]

SystemFinding
GeneralWell
Breasts and chest wallRight chest wall flat, no nodules or skin change; left breast without masses
Lymph nodesNo axillary, supraclavicular, or cervical nodes
ExtremitiesArm circumference 29.0 cm on each side; calves soft and non-tender
AbdomenSoft; liver not enlarged

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the upper outer quadrant of the right breast, stage IA (pT1c pN0(sn) M0), grade 2, estrogen and progesterone receptor positive, HER2 negative, recurrence score 14; treated by right total mastectomy with sentinel node biopsy and on adjuvant tamoxifen; synthetic modern counterpart of the documented 1931 breast cancer and mastectomyactiveconfirmed C50.411S — Synthetic tumor details and treatment; the diagnosis and the mastectomy are documented (D), but no tumor details from her lifetime are used.
Estrogen receptor positive status of the breast cancer (ER 90 percent, PR 60 percent)activeconfirmed Z17.0S — Synthetic receptor result; no receptor status from her lifetime is known.
Absence of the right breast after mastectomy with flat closure; she chose not to have reconstruction and not to wear an external prosthesisactiveconfirmed Z90.11S — Synthetic coding of the documented mastectomy; the decision about a prosthesis echoes her documented choice and is respected as her own.
Long-term use of tamoxifen as adjuvant endocrine therapyactiveconfirmed Z79.810S — Synthetic treatment status.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationCancer-related history and physical examinationEvery 3 to 6 months for the first 3 yearsCompleted todayNo symptoms or signs of recurrence
Medication safetyTamoxifen adherence and side effectsEvery visitCompleted todayTaken daily for eleven months
SurveyVasomotor symptom assessmentPeriodically on endocrine therapyCompleted todayOne or two mild hot flashes a day
ExaminationAbnormal vaginal bleeding inquiry on tamoxifenEvery visitCompleted todayRegular periods; no intermenstrual bleeding; yearly gynecologic assessment booked for the preventive visit
ExaminationVenous thromboembolism symptom inquiry on tamoxifenEvery visitCompleted todayNo leg swelling, calf pain, or breathlessness
ImagingDiagnostic mammogram of the left breastYearly after mastectomyUp to dateDone a week ago: BI-RADS 1; next in one year
ExaminationLymphedema assessment and risk-reduction counselingEvery visitCompleted todayNo swelling; arm circumferences equal
SurveyDepression screen (PHQ-2)At periodic intervalsCompleted todayPHQ-2 score 0
SurveyFatigue, cognitive concerns, and sexual or vaginal symptomsAt each visit or periodicallyCompleted todayNone reported
LaboratoryRoutine blood counts, chemistry, liver tests, and tumor markers (CEA, CA 15-3, CA 27.29)Not recommended in asymptomatic stage I to III survivorsNot indicatedNo symptoms to prompt testing; none ordered
ImagingCT, bone scan, PET, or other imaging for distant spreadNot recommended in asymptomatic survivorsNot indicatedNo symptoms; not ordered
ImagingBone density (DXA)Every 2 years on an aromatase inhibitor, on tamoxifen with ovarian suppression, or after chemotherapy-induced menopauseNot indicatedPremenopausal on tamoxifen alone; bone health by diet, vitamin D, and weight-bearing exercise
ReferralGenetic counselingOnceReferredAppointment next week
Self-managementSurvivorship care planWithin one year of completing primary treatmentCompleted todayWritten plan given and copied to medical oncology
Self-managementHealthy lifestyle counseling and second-cancer screeningEvery visitCompleted todayWalking about 200 minutes a week; cervical and colorectal screening to be addressed at the preventive visit next month

Goal progress:

Guideline basis: American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Breast Cancer Follow-Up and Management After Primary Treatment: ASCO Clinical Practice Guideline Update. J Clin Oncol 2013;31(7):961-965 (2013); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)

Follow-up: Genetic counseling next week. Adult preventive visit next month. Survivorship visit in January. Next scheduled visit 1979-10-19: adult preventive visit. [S]